You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Obinutuzumab for untreated advanced follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA513
  • Published:  21 March 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Draft guidance
  4. Invitation to participate

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 230 KB)

    Published:
    21 March 2018

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 458 KB)

    Published:
    09 February 2018
  • Committee papers (PDF 1.51 MB)

    Published:
    09 February 2018
  • Public committee slides (PDF 1.22 MB)

    Published:
    09 February 2018

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF 483 KB)

    Published:
    14 September 2017
  • Committee papers (PDF 29.76 MB)

    Published:
    14 September 2017
  • Public committee slides (PDF 1011 KB)

    Published:
    14 September 2017

Invitation to participate

  • Final scope (PDF 220 KB)

    Published:
    15 March 2017
  • Final matrix (PDF 263 KB)

    Published:
    15 March 2017
  • NICE's response to comments on the draft scope and provisional matrix (PDF 195 KB)

    Published:
    15 March 2017
  • Equality impact assessment (Scoping) (PDF 174 KB)

    Published:
    15 March 2017
Back to top